| Description | SR11237 is a Pan retinoid X receptor (RXR) agonist. SR11237 causes RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element. |
| In vitro | SR11237能有效通过RXRs激活COS-1细胞中的氯霉素乙酰转移酶报告基因，而不是通过视黄酸受体[2]。 |
| In vivo | 在Sprague-Dawley大鼠中，SR11237 (BMS-649) (25 mg/kg; i.p.) 引发骨骼形态和骨化作用的扰乱，包括生长板提前闭合以及骨化组织通过中央骺端的渗透[3]。 |
| Synonyms | SR 11237 |
| molecular weight | 380.48 |
| Molecular formula | C24H28O4 |
| CAS | 146670-40-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 4 mg/mL (10.51 mM), Sonication and heating to 60℃ are recommended. |
| References | 1. H.L. Dupuis. The RXR agonist SR-11237 affects skeletal development. ABSTRACT ONLY| VOLUME 24, SUPPLEMENT 1, S147, APRIL 01, 2016. 2. Gendimenico GJ, et al. A pleiotropic response is induced in F9 embryonal carcinoma cells and rhino mouse skin by All-trans-retinoic acid, a RAR agonist but not by SR11237, a RXR-selective agonist. J Invest Dermatol. 1994;102(5):676-680. 3. Dupuis H, et al. Exposure to the RXR Agonist SR11237 in Early Life Causes Disturbed Skeletal Morphogenesis in a Rat Model. Int J Mol Sci. 2019;20(20):5198. Published 2019 Oct 20. |